AI-powered MRI radiomics significantly improves prediction of treatment response in advanced liver cancer patients.
Key Details
- 1Multicenter study presented at ASCO 2025 focused on advanced hepatocellular carcinoma (HCC).
- 2AI-based radiomics model analyzed MRI data to predict response to atezolizumab and bevacizumab therapy.
- 3Study included 240 patients; training cohort of 161, validation cohort of 79.
- 4Radiomics model achieved AUC of 0.913 (training) and 0.825 (validation); combined with a key MRI feature, AUC increased to 0.951 and 0.835, respectively.
- 5Significant correlation found between radiomic and conventional MRI features for intrahepatic lesions.
Why It Matters
This work demonstrates the power of AI-driven radiomics to personalize cancer treatment planning, improve patient selection for liver cancer therapies, and highlights growing integration of advanced imaging analytics in clinical oncology workflows.
Source
AuntMinnie
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•AuntMinnie
AI Models Reveal Racial Disparities in Breast Cancer Patterns
Machine learning models reveal significant racial disparities and key predictors in breast cancer incidence across diverse groups.
•AuntMinnie
AI Algorithm Streamlines and Standardizes Shoulder Ultrasound Acquisition
A multitask AI system demonstrated high accuracy in standardizing and guiding shoulder musculoskeletal ultrasound imaging.